Cut Dominance Of Sun, Ranbaxy Combine, Says CUTS
This article was originally published in PharmAsia News
Executive Summary
A united Sun Pharma and Ranbaxy may become a strong global generics firm but its fallout on the Indian market is being studied carefully. Consumer activists have upped their ante raising concerns of impending market dominance in several areas.